GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)

6 Months Ended

Apr. 30, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill balances and movements for each reportable segment during the period

The following table presents goodwill balances and the movements for each of our reportable segments during the six months ended April 30, 2020:

	Life Sciences and Applied Markets			Diagnostics and Genomics			Agilent CrossLab			Total
	(in millions)
Goodwill as of October 31, 2019	$	1,438		$	1,594		$	561		$	3,593
Foreign currency translation impact	(4		)	(4		)	(3		)	(11		)
Goodwill as of April 30, 2020	$	1,434		$	1,590		$	558		$	3,582

Components of other intangible assets during the period

The components of other intangible assets as of April 30, 2020 and October 31, 2019 are shown in the table below:

	Purchased Other Intangible Assets
	Gross Carrying Amount		Accumulated Amortization		Net Book Value
	(in millions)
As of October 31, 2019
Purchased technology	$	1,413	$	763	$	650
Backlog	5		5		—
Trademark/Tradename	196		102		94
Customer relationships	329		87		242
Third-party technology and licenses	28		22		6
Total amortizable intangible assets	1,971		979		992
In-Process R&D	115		—		115
Total	$	2,086	$	979	$	1,107
As of April 30, 2020
Purchased technology	$	1,412	$	810	$	602
Trademark/Tradename	196		110		86
Customer relationships	328		123		205
Third-party technology and licenses	28		23		5
Total amortizable intangible assets	1,964		1,066		898
In-Process R&D	23		—		23
Total	$	1,987	$	1,066	$	921

Schedule of estimated future amortization expense of finite-lived intangible assets

Future amortization expense related to existing finite-lived purchased intangible assets for the remainder of fiscal year 2020 and for each of the five succeeding fiscal years and thereafter is estimated below:

Estimated future amortization expense:
(in millions)
Remainder of 2020	$	91
2021	$	172
2022	$	150
2023	$	107
2024	$	86
2025	$	68
Thereafter	$	224